136 related articles for article (PubMed ID: 25415135)
1. The T309G murine double minute 2 gene polymorphism is an independent prognostic factor for patients with renal cell carcinoma.
de Martino M; Taus C; Wessely IS; Lucca I; Hofbauer SL; Haitel A; Shariat SF; Klatte T
DNA Cell Biol; 2015 Feb; 34(2):107-12. PubMed ID: 25415135
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
3. Role of MDM2 T309G polymorphism in susceptibility and prognosis of nonsmall cell lung cancer: a meta-analysis.
Kong Q; Li P; Tian Q; Ha MW
Genet Test Mol Biomarkers; 2014 May; 18(5):357-65. PubMed ID: 24673452
[TBL] [Abstract][Full Text] [Related]
4. Association between murine double minute 2 T309G polymorphism and risk of liver cancer.
Tang T; Song X; Yang Z; Huang L; Wang W; Tan H
Tumour Biol; 2014 Nov; 35(11):11353-7. PubMed ID: 25119589
[TBL] [Abstract][Full Text] [Related]
5. Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish Population.
Yilmaz M; Tas A; Donmez G; Kacan T; Silig Y
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1059-1062. PubMed ID: 29699057
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of the MDM2 T309G polymorphism and gastric cancer risk.
Song B; Duan ZY; Zhong YH; Lei N; Yang YQ; Luo KY
Asian Pac J Cancer Prev; 2014 Jan; 14(11):6649-51. PubMed ID: 24377582
[TBL] [Abstract][Full Text] [Related]
7. Murine Double Minute 2 SNP T309G Polymorphism and Urinary Tract Cancer Risk: A Meta-Analysis.
Ding H; Dai Y; Ning Z; Fan N; Wang Z; Li P; Zhang L; Tao Y; Wang H
Medicine (Baltimore); 2016 Mar; 95(12):e2941. PubMed ID: 27015167
[TBL] [Abstract][Full Text] [Related]
8. The MDM2 T309G polymorphism and risk of lung cancer: an updated meta-analysis of 10,186 cases and 14,155 controls.
Tian X; Wang B; Guo J; Liu X; Zhang T; Liang C; Zhou N; Hou X; Ma Y; Yu H; Chen L; Ren Z; Fan K; Tian Q
Panminerva Med; 2016 Dec; 58(4):341-348. PubMed ID: 27171940
[TBL] [Abstract][Full Text] [Related]
9. Relationship Between Murine Double Minute 2 (MDM2) T309G Polymorphism and Endometrial Cancer Risk: A Meta-Analysis.
Xue Z; Zhu X; Teng Y
Med Sci Monit; 2016 Sep; 22():3186-90. PubMed ID: 27604213
[TBL] [Abstract][Full Text] [Related]
10. The polymorphisms of P53 codon 72 and MDM2 SNP309 and renal cell carcinoma risk in a low arsenic exposure area.
Huang CY; Su CT; Chu JS; Huang SP; Pu YS; Yang HY; Chung CJ; Wu CC; Hsueh YM
Toxicol Appl Pharmacol; 2011 Dec; 257(3):349-55. PubMed ID: 21982800
[TBL] [Abstract][Full Text] [Related]
11. Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.
Yan YL; Han F; Tan WM; Wu CP; Qin X
Asian Pac J Cancer Prev; 2014; 15(16):6767-72. PubMed ID: 25169523
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D receptor gene polymorphisms are associated with increased risk and progression of renal cell carcinoma in a Japanese population.
Obara W; Suzuki Y; Kato K; Tanji S; Konda R; Fujioka T
Int J Urol; 2007 Jun; 14(6):483-7. PubMed ID: 17593089
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia and renal cell carcinoma: The influence of HIF1A+1772C/T functional genetic polymorphism on prognosis.
Ferreira M; Teixeira A; Maurício J; Lobo F; Morais A; Medeiros R
Urol Oncol; 2017 Aug; 35(8):532.e25-532.e30. PubMed ID: 28476527
[TBL] [Abstract][Full Text] [Related]
14. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
[TBL] [Abstract][Full Text] [Related]
15. Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival.
Toffoli G; Biason P; Russo A; De Mattia E; Cecchin E; Hattinger CM; Pasello M; Alberghini M; Ferrari C; Scotlandi K; Picci P; Serra M
Clin Cancer Res; 2009 May; 15(10):3550-6. PubMed ID: 19451596
[TBL] [Abstract][Full Text] [Related]
16. The protease activated receptor 1 gene variation IVSn -14 A>T is associated with distant metastasis and cancer specific survival in renal cell carcinoma.
de Martino M; Haitel A; Schatzl G; Klatte T
J Urol; 2013 Oct; 190(4):1392-7. PubMed ID: 23517743
[TBL] [Abstract][Full Text] [Related]
17. Risk of renal cell carcinoma and polymorphism in phase I xenobiotic metabolizing CYP1A1 and CYP2D6 enzymes.
Ahmad ST; Arjumand W; Seth A; Nafees S; Rashid S; Ali N; Hamiza OO; Sultana S
Urol Oncol; 2013 Oct; 31(7):1350-7. PubMed ID: 22281432
[TBL] [Abstract][Full Text] [Related]
18. No association of MDM2 T309G polymorphism with susceptibility to Korean gastric cancer patients.
Cho YG; Choi BJ; Song JH; Kim CJ; Cao Z; Nam SW; Lee JY; Park WS
Neoplasma; 2008; 55(3):256-60. PubMed ID: 18348658
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of associations between the MDM2-T309G polymorphism and prostate cancer risk.
Chen T; Yi SH; Liu XY; Liu ZG
Asian Pac J Cancer Prev; 2012; 13(9):4327-30. PubMed ID: 23167337
[TBL] [Abstract][Full Text] [Related]
20. Association of MDM2 SNP309 variation with lung cancer risk: evidence from 7196 cases and 8456 controls.
Zhuo W; Zhang L; Zhu B; Ling J; Chen Z
PLoS One; 2012; 7(7):e41546. PubMed ID: 22844496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
